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A B S T R A C T
The antiepileptic drug ethosuximide has recently been shown to be neuroprotective in various Caenorhabditis
elegans and rodent neurodegeneration models. It is therefore a promising repurposing candidate for the treat-
ment of multiple neurodegenerative diseases. However, high concentrations of the drug are required for its
protective effects in animal models, which may impact on its translational potential and impede the identifi-
cation of its molecular mechanism of action. Therefore, we set out to develop more potent neuroprotective lead
compounds based on ethosuximide as a starting scaffold. Chemoinformatic approaches were used to identify
compounds with structural similarity to ethosuximide and to prioritise these based on good predicated blood-
brain barrier permeability and C. elegans bioaccumulation properties. Selected compounds were initially
screened for anti-convulsant activity in a C. elegans pentylenetetrazol-induced seizure assay, as a rapid primary
readout of bioactivity; and then assessed for neuroprotective properties in a C. elegans TDP-43 proteinopathy
model based on pan-neuronal expression of human A315T mutant TDP-43. The most potent compound screened,
α-methyl-α-phenylsuccinimide (MPS), ameliorated the locomotion defects and extended the shortened lifespan
of TDP-43 mutant worms. MPS also directly protected against neurodegeneration by reducing the number of
neuronal breaks and cell body losses in GFP-labelled GABAergic motor neurons. Importantly, optimal neuro-
protection was exhibited by external application of 50 μM MPS, compared to 8mM for ethosuximide. This
greater potency of MPS was not due to bioaccumulation to higher internal levels within the worm, based on 1H-
nuclear magnetic resonance analysis. Like ethosuximide, the activity of MPS was abolished by mutation of the
evolutionarily conserved FOXO transcription factor, daf-16, suggesting that both compounds act via the same
neuroprotective pathway(s).
In conclusion, we have revealed a novel neuroprotective activity of MPS that is> 100-fold more potent than
ethosuximide. This increased potency will facilitate future biochemical studies to identify the direct molecular
target(s) of both compounds, as we have shown here that they share a common downstream DAF-16-dependent
mechanism of action. Furthermore, MPS is the active metabolite of another approved antiepileptic drug,
methsuximide. Therefore, methsuximide may have repurposing potential for treatment of TDP-43 proteino-
pathies and possibly other human neurodegenerative diseases.
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With the predicted growth of the global ageing population, cases of
age-associated neurodegenerative diseases such as Alzheimer's disease
(AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS)
are expected to rise (Arthur et al., 2016). However, most current
therapies do not decelerate or modify disease, and efforts to develop
new treatments have been met with high attrition rates. Drug devel-
opment efforts have largely focused on treating each neurodegenerative
condition separately, however our currently limited understanding of
disease-specific pathogenic mechanisms is a major impediment to this
strategy. Despite their pathological and clinical heterogeneity, several
underlying features are common to apparently distinct neurodegen-
erative diseases, such as protein aggregation, inflammation and prion-
like propagation (Smith and Mallucci, 2016; Frank-Cannon et al., 2009;
Brettschneider et al., 2015). Although disease-specific targets are un-
doubtedly of major importance for finding treatments for neurode-
generation, these common features could potentially be targeted as a
complementary more general therapeutic strategy. Moreover, com-
pounds that confer neuroprotection in multiple neurodegenerative
disease models are likely to target such common features; and therefore
may be useful as novel therapies and to facilitate identification of
general neuroprotective mechanisms (Chen et al., 2015a).
The nematode Caenorhabditis elegans is an attractive choice of or-
ganism for modelling age-related neurodegenerative diseases (Chen
et al., 2015a; Li and Le, 2013; Sleigh et al., 2011). Its short lifespan of
around 3weeks means that age-dependent neurodegenerative pheno-
types can be assessed quickly and without the ethical constraints as-
sociated with complex model systems such as rodents. The simple
nervous system of C. elegans coupled with its ease of genetic manip-
ulation facilitates the development of genetic disease models of neu-
rodegeneration and for delineating disease processes via chemical and
genetic screens. Additionally, C. elegans has a transparent body which
enables age-dependent degeneration of fluorescently-labelled neurons
to be studied in vivo. In recent years, chemical screens of approved
drugs in numerous C. elegans models of human neurodegenerative
diseases have identified a chemically-diverse set of compounds with
neuroprotective effects (McCormick et al., 2013; Gutierrez-Zepeda
et al., 2005; Abbas and Wink, 2010; Smith and Luo, 2003; Lublin et al.,
2011; Jagota and Rajadas, 2012; Keowkase et al., 2010; Arya et al.,
2009; Alavez et al., 2011; Voisine et al., 2007; Kashyap et al., 2014;
Tauffenberger et al., 2013; Chen et al., 2015b). However, most of these
compounds have only been assessed in a single disease model and their
extent of neuroprotection across multiple neurodegenerative diseases is
therefore largely unknown. One notable exception is the antiepileptic
drug (AED) ethosuximide, which is still used as a first line treatment for
children with absence seizures (Goren and Onat, 2007). Early, pio-
neering work from the Kornfeld lab discovered that ethosuximide
treatment increased the lifespan of wild type C. elegans (Evason et al.,
2005; Collins et al., 2008). Subsequently, ethosuximide was shown to
confer neuroprotection in three different C. elegans neurodegeneration
models: ALS (Tauffenberger et al., 2013), frontotemporal dementia
with parkinsonism-17 (Chen et al., 2015b) and adult-onset neuronal
ceroid lipofuscinosis (Chen et al., 2015b). Importantly, ethosuximide's
neuroprotective effects are not limited to worms, as it has also been
shown to be protective in a mammalian neuroblastoma cell culture
model of Huntington's disease (Chen et al., 2015b). Furthermore,
ethosuximide ameliorated neuronal death and cognitive deficits in a rat
in vivo amyloid beta toxin-induced AD model (Tiwari et al., 2015),
suggesting the feasibility of translating its protective effects clinically
and for repurposing it as a general neuroprotective agent.
Ethosuximide has been variously suggested to exert its antiepileptic
action by inhibiting T-type calcium channels (Coulter et al., 1989a;
Coulter et al., 1990; Coulter et al., 1989b; Gomora et al., 2001;
Lacinova et al., 2000), voltage-gated sodium channels and potassium
channels (Fohlmeister et al., 1984). In contrast, neuroprotection and
lifespan extension by ethosuximide appears to be independent of T-type
calcium channels (Chen et al., 2015b; Evason et al., 2005) and instead
has been linked to altered activity of forkhead box O (FOXO) tran-
scription factors (Chen et al., 2015b), and the phosphoinositide 3-ki-
nase (PI3K)/protein kinase B (AKT)/Wnt/β-catenin pathway (Tiwari
et al., 2015). Nevertheless, the molecular mechanism of action of
ethosuximide remains unclear and no data have been reported on the
direct molecular target of this widely prescribed AED.
Identification of a drug's molecular target is classically performed by
affinity chromatography methods, which involves drug derivatisation
for immobilisation onto an affinity matrix (Terstappen et al., 2007).
Successful identification of molecular targets using this approach ty-
pically requires femtomolar to low micromolar affinities of the drug for
its specific binding protein. However, the therapeutic range of etho-
suximide in human epilepsy is 280–700 μM (Goren and Onat, 2007) and
its neuroprotective effects in animal models require millimolar levels of
the drug (Chen et al., 2015a). This low potency of ethosuximide may
explain why its direct molecular target(s) have remained unknown
despite being prescribed for 60 years. We reasoned that screening for
structurally similar compounds with greater potency than ethosuximide
could reveal novel neuroprotective compounds with translational po-
tential that might also be used to identify shared direct molecular tar-
gets. To this end, here we report that α-methyl-α-phenylsuccinimide
(MPS), confers neuroprotection and lifespan-extension in a C. elegans
model of TDP-43 proteinopathy at a> 100-fold enhanced potency
compared to ethosuximide; and establish a common downstream me-
chanism of action for ethosuximide and MPS via the C. elegans DAF-16
FOXO transcription factor.
2. Methods
2.1. Maintenance and propagation of C. elegans strains
C. elegans strains were cultured at 20 °C on Nematode Growth Media
(NGM; 1mM each of CaCl2 and MgSO4, 25mM KH2PO4, 5 μg/mL
cholesterol, and in w/v 2% agar, 0.25% peptone, and 0.3% NaCl) agar
culture plates seeded with the E. coli strain OP50. The C. elegans wild-
type (WT) Bristol N2, unc-49 (e407) III, and daf-16 (mu86) I strains
were obtained from Caenorhabditis Genetics Center (CGC, University of
Minnesota, USA), whilst the human TDP-43-expressing strain CK426
[Psnb-1::TDP-43A315T, Pmyo-2::dsRED] was generated by Dr. Brian
Kraemer (University of Washington, USA) (Kraemer et al., 2003;
Kraemer and Schellenberg, 2007; Liachko et al., 2010a), who also
provided the GABAergic neuron reporter strain CZ1200 [Punc-25::GFP]
from Prof. Yishi Jin (University of California, San Diego, USA).
2.2. Drug treatment
All chemicals were obtained from Sigma Chemical Co. (St. Louis,
MO), except compounds 12 and 13, which were from Enamine Ltd.
(Monmouth Jct., NJ); and compound 18, which was synthesized in-
house. Treatment NGM plates containing water-soluble compounds
succinimide and ethosuximide were prepared from concentrated stocks
in agar-free NGM which were added to molten NGM agar before
pouring into petri dishes. Treatment plates containing the hydrophobic
compound MPS in 0.4% dimethyl sulfoxide (DMSO) vehicle, and cor-
responding vehicle plates, were similarly prepared from concentrated
stocks with DMSO in agar-free NGM. Freshly poured plates were stored
in the dark at 4 °C after drying at room temperature overnight, and
transferred to room temperature and seeded up to 4 days before use.
Worms age-synchronised via bleaching were chronically-exposed to
treatments on plates from the L1 larval stage onwards. L1 arrest was
performed by incubating bleached worms as previously described
(Kashyap et al., 2014) in M9 buffer (1 mM MgSO4, 3 g/L KH2PO4, 5 g/L
NaCl, and 6 g/L Na2HPO4) for at least 24 h (Porta-de-la-Riva et al.,
2012), followed by deposition of L1 worms onto the OP50 lawn on
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treatment plates. Liquid-based treatment solutions for PTZ-induced
seizure assays were prepared by diluting compounds at their required
concentrations in 0.1% bovine serum albumin (BSA) in Dent's Ringer
solution (DRS pH 7.4; 1 mM MgCl2, 3mM CaCl2, 6 mM KCl, 10mM
HEPES, and 140mM NaCl) with and without 7mg/mL pentylenete-
trazol (PTZ).
2.3. Behavioural and lifespan assays
All assays were performed at 20 °C. Seizure assays were based on a
previously-described method (Williams et al., 2004), whereby treat-
ment with the pro-convulsant pentylenetetrazole (PTZ) induces char-
acteristic repetitive ‘head bobbing’ seizures in worms containing null
mutations in the GABAA-receptor-encoding gene unc-49. Briefly, un-
synchronised 1–3-day-old adult worms were pre-incubated in liquid
droplets containing ethosuximide-based compounds in DRS for 2 h prior
to treatment with 7mg/mL PTZ in DRS for 15 mins, at which point the
number of ‘head bobs’ was quantified for 30 s. Seizures were defined as
head bobbing movements manifested by head extension from the body
followed by shrinkage back into the body, and were scored in a quali-
tative and quantitative manner. Qualitative scoring simply assessed
whether individual worms were undergoing seizures, as defined by
exhibiting at least three repetitive head bobs over the scoring duration;
whereas the quantitative approach scored the total number of head
bobs over the same duration. DMSO-soluble compounds were assayed
at a DMSO concentration of 1%, as pretreatment with 1% DMSO did not
cause any observable abnormality in the worms' behaviour, with 100%
of worms seizing in response to PTZ. Toxicity was determined by visual
observations of abnormal stiff movement or immobility, and a weak
response to touch or death as indicated by the absence of response to
touch at the end of drug pre-treatment and/or PTZ exposure. Con-
versely, a therapeutic effect was defined by a reduction or abolishment
of seizures in the presence of movement and response to touch. If ab-
sence of seizures was observed with immobility, a non-seizing pheno-
type was scored only if a robust response to touch was observed, in-
dicative of non-toxicity.
Motility and lifespan assays were performed on age-synchronised
strains. Motility was assessed by quantifying the number of body bends
in the unparalysed posterior half of these strains on unseeded treatment
NGM plates for 1min after 20 s of acclimatisation. Scoring was per-
formed when sinusoidal, lateral, or coiling movements deviate maxi-
mally from and back to the original position. Lifespan assays were in-
itiated with 60 day-1 adults which were scored for survival every
alternate day, and concluded when all worms were dead. To prevent
progeny contamination, worms were concurrently transferred to freshly
seeded treatment plates with each assay day. Worms were scored as
alive in the presence of spontaneous locomotion, locomotive responses
to touch stimulation with a worm pick, and/or pharyngeal pumping.
Missing and dead worms which displayed internally-hatched progenies
or visible signs of physical damage such as gut spillage or gonad ex-
trusion were censored from analysis.
2.4. In vivo GABAergic neuronal imaging
Live, age-synchronised worms were immobilised in polyethylene
glycol (PEG)/glycerol solution in 1× phosphate buffered saline (PBS)
(20% each of PEG (w/v) and glycerol) on a 22×40mm imaging slide
(VWR International, Pennsylvania, USA). Slides were then mounted
with a 13-mm coverslip (Paul Marienfeld GmbH & Co. KG, Germany)
and imaged under fluorescence with a Nikon Eclipse Ti S microscope
(Nikon Instruments Europe BV, Netherlands) to visualise GFP-labelled
GABAergic neurons. Quantification of neuronal cell bodies and breaks
of the D-type GABAergic inhibitory motor neurons in the ventral nerve
cord was carried out using NIS-Elements imaging software version 3.2
(Nikon Instruments Europe BV, Netherlands). Cell bodies were scored
when intact and clear punctate fluorescence was observed, whilst
neuronal breaks were quantified from breaks in the fluorescence within
the neuronal subset.
2.5. Genetic crosses
N2 males were mated with CK426 [Psnb-1::TDP-43A315T, Pmyo-
2::dsRED] hermaphrodites, and resulting transgenic male offspring
were crossed with CZ1200 [Punc-25::GFP] hermaphrodites to obtain
uncoordinated hermaphrodites which express both pharyngeal dsRED
and GABAergic neuronal GFP markers. Progenies from these worms
were genotyped to verify presence of the human TDP-43-encoding
TARDBP gene via PCR using primers which target the transgene [for-
ward: 5′-CTGAATATATTCGGGTAACCG-3′; reverse: 5′- CAGCCAGAAG
ACTTAGAATCC-3′] and TDP-43 protein expression via immunoblotting
using a mouse monoclonal anti-TDP-43 primary antibody (Abcam,
Cambridge, UK) at 1:1000 dilution. This new strain was given the
designation AMG619 [Psnb-1::TDP-43A315T, Pmyo-2::dsRED; Punc-
25::GFP]. To introduce a deletion in the daf-16 allele in AMG619
worms, daf-16 (mu86) I hermaphrodites were first mated with N2 males
and daf-16 (mu86) I male progenies were then crossed with AMG619
hermaphrodites. As there is no visible selection marker for the daf-16
(mu86) I allele, hermaphrodite progenies were selected using the
fluorescent markers and uncoordinated phenotype for AMG619.
Homozygosity for the daf-16 (mu86) I deletion was verified with PCR
using primers which distinguished between the mutation [forward:
5′-CCCACATTCGTGTGGGTTTTCTAGTCG-3′; reverse: 5′-CGTTATCAA
ATGCTCCTTGCATTGAATC-3′] and the wildtype daf-16 allele [forward:
5′-CCCACATTCGTGTGGGTTTTCTAGTCG-3′; reverse: 5′-GCGTCAGTT
CCGATCTGATATGAAC-3′], and presence of the TARDBP gene was
verified as before. This new strain was given the designation AMG620
[daf-16 (mu86) I; Psnb-1::TDP-43A315T, Pmyo-2::dsRED; Punc-25::GFP].
2.6. Selection of primary screening compounds
Structurally-similar compounds to ethosuximide were selected em-
pirically or extracted from the ZINC database version 12 (Irwin and
Shoichet, 2005) based on substructure search (Barnard, 1993) and 70 to
90% molecular similarity as measured with the Tanimoto coefficient
(Tc) (Holliday et al., 2002). Further compound refinement to select the
most optimal molecules for screening was guided with the Accelrys
Pipeline Pilot™ software version 9.0 (Accelrys Software Inc., California,
USA) to rank compounds with an aqueous solubility (LogS) cut off value
of −4.5 via the “Pareto Sort” function based on overall optimality for
the following parameters: 1) central nervous system (CNS) permeability
as predicted from the CNS multiparameter optimisation (MPO) algo-
rithm (Wager et al., 2010), 2) Tc similarity to ethosuximide, and 3) C.
elegans bioaccumulation propensity predicted from a worm structure-
based accumulation (SAM) model (Burns et al., 2010) (Fig. 1).
2.7. Chemical synthesis
Compound 18 (2,5-Pyrrolidinedione,3-ethyl-1,3-dimethyl) is an N-
methylated form of ethosuximide and was generated from ethosux-
imide in a single step reaction with the methylating agent iodomethane
in anhydrous conditions, as adapted from a previously reported pro-
cedure (Khan et al., 2001). The reaction was initially left to react at
room temperature for 3 days and continued for an additional night with
half the original amount of iodomethane (6.8 mM). Analytical thin
layer chromatography performed on a silica gel-coated aluminium plate
was used to verify successful generation of the N-methylated product.
The reaction mixture was then subjected to filtration and reduced
pressure to remove K2CO3 and acetone, respectively. The product was
purified by silica gel column chromatography at hexane/ethyl
acetate= 4/1 and confirmed for its identity after solvent removal from
combined appropriate fractions.
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Fig. 1. Workflow for identification of structurally-similar compounds to ethosuximide. Compounds for screening were identified and selected empirically and from
the ZINC database, and were ranked for their optimality based on predicted CNS permeability (Holliday et al., 2002) and C. elegans bioaccumulation (Wager et al.,
2010), and the extent of similarity to ethosuximide using Pipeline Pilot™.
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2.8. Measuring internal drug concentration in C. elegans with 1D 1H NMR
spectroscopy
Synchronised CK426 L1 worms were cultured at 3000 worms per
treatment plate seeded with 100 μL OP50. At 70 h post L1-plating, day 1
adults were washed off plates and cleaned with M9 buffer thrice
through pelleting by gravity for 6 mins. Worms were transferred to
Corning® Costar® Spin-X® tube filters and spun at 450 g for 1.5 mins to
remove excess liquid, followed by resuspension in water and transferral
to Eppendorf® LoBind microcentrifuge tubes. Five percent of the worm
suspension was set aside for estimating the analysed sample size and the
final worm wash solution was checked by NMR to ensure that all
treatment peaks observed in the extracts originated from within the
worms.
Metabolites were extracted from samples with 100mM of the NMR
reference compound sodium trimethylsilyl-2H4-propionate (TSP) in
50% (v/v) water and ice-cold acetonitrile (AcN). This was performed on
an ice bath via sonication with an MSE Soniprep 150 Plus sonicator/cell
disruptor (Wolf Laboratories Ltd., York, UK) at a fixed frequency of
50 kHz for three 30-s durations with 30-s rest intervals between and
10% amplitude as adapted from previously described protocols (Khan
et al., 2001). Samples were vortexed for 30 s and centrifuged at
21,000×g for 5 mins at 4 °C, followed by snap-freezing of metabolite-
containing supernatants in liquid nitrogen and lyophilisation to com-
pletion with a Heto PowerDry LL1500 freeze dryer (ThermoFisher
Scientific Inc). Immediately prior to 1D 1H NMR spectroscopy analysis,
200 μL of deuterated phosphate buffer (0.0012 and 100mM of sodium
azide and sodium phosphate pH 7.4 in deuterated water (Goss Scientific
Instruments, Cheshire, UK)) were added to lyophilised extracts, vor-
texed for 1min, and centrifuged at 12,000×g for 2 mins at 20-25 °C.
The clarified extracts were each transferred to clean 3-mm outer dia-
meter NMR SampleJet tubes (Bruker BioSpin Gmbh) and analysed by
1D 1H NMR spectroscopy using a Bruker Avance III NMR spectrometer
equipped with a 5mm TCI CryoProbe with a proton resonance fre-
quency of 600MHz (Bruker BioSpin Gmbh). 1D 1H spectra were ac-
quired at 25 °C on TopSpin™ version 3.5pl6 (Bruker BioSpin Gmbh),
with the manufacturer-provided nuclear Overhauser enhancement
spectroscopy (noegpr1d) and Carr-Purcell-Meiboom-Gill (cpmgpr1d)
pulse sequences and automatically processed, referenced and phased
using vendor supplied routines (apk0.noe). Calculation of internal
compound concentrations was based on the published volume of 4 nL
for a day 1 adult worm of the wild type N2 strain at approximately 85 h
post-hatch (Hirose et al., 2003), based on the sum of around 15 h for
development to L1-arrest after hatching at 20 °C and sample processing
at 70 h post L1-arrest.
2.9. Statistical analysis
All general statistical analyses were performed on GraphPad Prism
version 6 (GraphPad Software Inc., California, USA), except analyses
and comparison of lifespan which were carried out with the log-rank
test on the Online Application for the Survival Analysis of Lifespan
Assays 2 (OASIS 2;(Han et al., 2016)). Concentration-response curves
were fitted with GraphPad Prism 6 via nonlinear regression with the
variable slope model, followed by subsequent derivation and statistical
comparison of LogEC50 values. Data is presented as mean values, with
standard error of mean when appropriate.
3. Results
3.1. Chemoinformatic selection and synthesis of ethosuximide-based
compounds
In order to identify molecules with similarity to ethosuximide and
prioritise these for screening in C. elegans, we employed computational
chemistry approaches (Fig. 1). Initially, compounds similar to both
ethosuximide and its biologically inert parent compound succinimide
were retrieved from the ZINC database. This was performed based on
both substructure search and similarity searching using Tc thresholds of
at least 70%, which are generally considered to represent high simi-
larity (Sheridan and Kearsley, 2002). Identified compounds were sub-
jected to subsequent analysis on the Pipeline Pilot™ program to narrow
down the pool so as to facilitate the selection of compounds for
screening (Fig. 1). Since succinimide and ethosuximide are themselves
structurally similar, and as the goal was to derive bioactive compounds
similar to ethosuximide for initial screening, identified compounds si-
milar to inert succinimide were tagged and removed such that only
compounds similar to ethosuximide remained for selection. Aqueous
solubility is an important parameter for drugs acting on the central
nervous system (CNS), as> 85 and 90% of approved CNS drugs have
been found to have LogS values greater than −4 and −5mol/L, re-
spectively (Alelyunas et al., 2010). Hence, identified ethosuximide-si-
milar compounds that remained in the Pipeline Pilot™ analysis were
therefore subjected to a solubility filter with an intermediate LogS cut-
off of at least −4.5 to remove those which did not fufill this solubility
criterion. Retained compounds with desirable solubilities were subse-
quently ranked for their overall optimality, based on structural simi-
larity to ethosuximide and predicted C. elegans bioaccumulation pro-
pensity (Burns et al., 2010), by maximising for all parameters with a
multiparameter optimisation (MPO) approach. Compound selection
was additionally aided by empirical medicinal chemistry expertise to
prioritise computationally identified and ranked compounds, and to
identify existing potential chemical spaces and approved drugs with
some similarity to ethosuximide which may have been excluded from
initial computational detection.
A total of 18 compounds were thereby selected for screening, in-
cluding ethosuximide and succinimide, which were to be utilised as
positive and negative controls respectively (Fig. 2). Due to the small
number of compounds analysed at this stage, the predicted CNS per-
meability was additionally manually curated for each compound using
the CNS MPO algorithm (Wager et al., 2010), and fed into the Pipeline
Pilot™ analysis as an additional MPO parameter for compound ranking.
All selected compounds were predicted to possess good CNS perme-
ability as evident from high CNS MPO scores ranging from 4.3 to a
perfect score of 6 (Table S1; scores of ≥4 are considered to be high
(Wager et al., 2010)). Overall the selected compounds displayed good
predicted permeation of the CNS, small differences in predicted C.
elegans bioaccumulation, and a good overall ranking, confirming their
optimality for screening (Table S2). With the exception of compound 18
(2,5-Pyrrolidinedione,3-ethyl-1,3-dimethyl), all molecules were avail-
able and obtained from commercial suppliers. Compound 18 was syn-
thesized via a single step N-methylation reaction of ethosuximide using
iodomethane and subsequently purified by thin layer chromatography.
3.2. Primary screen for in vivo bioactivity in C. elegans
Neurodegeneration phenotypes are most evident in aged animals
and involve time consuming, labour-intensive assays. As ethosuximide
is an anti-epileptic drug, we took advantage of a previously described
worm PTZ-induced seizure assay (Williams et al., 2004) to develop a
more rapid primary screening platform to identify bioactive molecules
amongst our selected set of ethosuximide-related compounds. The
characteristic head-bobbing convulsions induced by PTZ in worms
containing null mutations in the GABAA-receptor-encoding gene unc-49
were unaffected by the biologically inert succinimide molecule (Movie
S1), but were greatly reduced by the structurally-related compound
ethosuximide (Movie S2). This therefore confirmed the validity of the
PTZ assay for screening for bioactive anticonvulsant molecules. Several
compounds were unable to be assessed due to solubility problems based
on the conditions required for the assay, namely compounds 3 (phe-
nytoin), 5 (thalidomide), 6 (phthalimide), 8 (N-phenylphthalimide),
and 10 (1-benzylpyrrolidine-2,5-dione). The remaining compounds
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Fig. 2. Set of compounds selected for screening. Chemoinformatic and empirical approaches were used to identify molecules with similarity to ethosuximide that had
desirable properties and high predicted blood-brain barrier permeability.
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were first subjected to a preliminary screen against ethosuximide and
succinimide at a single optimal reference ethosuximide concentration of
4mg/mL, or 2mg/mL in the event of observed toxicity at 4mg/mL.
This initial pre-screen identified compounds 9 (α-methyl-α-phe-
nylsuccinimide), 11 (α-methyl-α-propylsuccinimide), 12 (3,3-diethyl-
pyrrolidine-2,5-dione), 13 (4-ethyl-4-methylpyrrolidin-2-one), 14 (α,α-
dimethyl-β-methylsuccinimide), 15 (3,3-diethylpyrrolidin-2-one), 16
(methsuximide), 17 (phensuximide), and 18 (2,5-pyrrolidinedione,3-
ethyl-1,3-dimethyl) as active in reducing both the percentage of ani-
mals undergoing seizures (Fig. S1A) and the frequency of seizures (Fig.
S1B). Like ethosuximide, these active compounds protected against
seizures when screened at 2 or 4mg/mL, or when re-screened at a
higher concentration of 10mg/mL if activity was not seen at the lower
concentrations. Compound 7 (2-pyrrolidine) was not protective against
induced seizures even at 10mg/mL, and was therefore classified as
inactive. Although the effect of compound 4 (trimethadione) on the
frequency of seizures was not statistically significant at 4mg/mL, it
produced a partial reduction in the percentage of animals undergoing
seizures, and so it was further assayed alongside all the active com-
pounds across a wide range of concentrations for subsequent potency
assessment (Fig. 3). The resultant concentration-response curves gen-
erally exhibited the same shift patterns from ethosuximide for both
qualitative (percentage of worms seizing in the population) and quan-
titative (mean frequency of seizures) scoring approaches (Fig. 3A,B).
Compounds 4, 11, 12, 13, 15, 17 and 18 exhibited either no significant
difference from ethosuximide or were significantly less potent, as in-
dicated by up to 4-fold higher EC50 values (Table S3). In contrast,
compounds 9, 14 and 16 were significantly more potent, with ap-
proximately 2-fold lower EC50 values in comparison to ethosuximide's
EC50 of 9.7 mM. To better emphasize these potency differences, antic-
onvulsive effects were compared at a single concentration of 7.5 mM
(Fig. 3C). This clearly demonstrated that seizure protection by com-
pounds 9, 14, and 16 was greatly improved in comparison to etho-
suximide at the same concentration.
3.3. Compound 9 (α-methyl-α-phenylsuccinimide) is neuroprotective
Of the three compounds with similarly enhanced potencies, com-
pound 9 (α-methyl-α-phenylsuccinimide; MPS) was selected for further
study, based on considerations of cost and the presence of a phenyl
Fig. 3. Compound screen for bioactivity using a
worm seizure assay. Worms were pre-treated for 2 h
with the indicated concentration of compounds and
then incubated for a further 15 mins in the same
solution with 7mg/mL pentylenetetrazole added. At
this point, head-bobbing seizures were assessed over
a time period of 30 s. Concentration-response curves
were derived from scoring of (A) percentages of
seizing worms and (B) frequencies of seizures in unc-
49 worms. Significant leftward shifts of curves from
compounds 9, 14, and 16 in comparison to that of
ethosuximide are indicative of enhanced potencies in
comparison to the drug (p < .05). Data shown was
pooled from three biological replicates. Curve fit and
significance of shifts, as derived from comparisons of
fitted LogEC50 values, were performed via nonlinear
regression analysis (n=5–15 worms per concentra-
tion per compound). (C) Seizure-protecting activities
of compounds was compared at a single concentra-
tion of 7.5 mM. Compounds 9, 11, 14, and 16 greatly
reduced seizure rates as compared to ethosuximide
at the same concentration (p < .05). Data shown
was pooled from three biological replicates, with
comparisons made via the Kruskal-Wallis test with
Dunn's multiple comparison (n=14–15 worms per
concentration per compound); *, p < .05.
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moiety that would facilitate future medicinal chemistry approaches to
improve its potency and physicochemical properties further.
Neuroprotective activity was assessed in a C. elegans transgenic model
of TDP-43 proteinopathy (Liachko et al., 2010a). This strain pan-neu-
ronally expresses a missense mutation in the human TARDBP gene that
results in an A315T mutated form of the RNA-binding protein TDP-43,
which is known to cause familial ALS (Gitcho et al., 2008; Sreedharan
et al., 2008). Importantly, the impaired movement, reduced lifespan
and neurodegeneration exhibited by worms expressing pan-neuronal
TDP-43(A315T) has previously been shown to be ameliorated by
ethosuximide (Tauffenberger et al., 2013), thereby justifying its use. We
first determined the effect of a range of concentrations of MPS on lo-
comotion, by quantifying the frequency of body bends on agar. MPS
increased locomotion in worms of over 3 days of age, with the most
consistent significant effect observed at 0.05mM (Fig. 4). We therefore
compared the effect of 0.05mM MPS to that of ethosuximide at its
previously determined optimal neuroprotective concentration of 8mM
(Chen et al., 2015b). At these concentrations, ethosuximide sig-
nificantly increased the frequency of body bends in TDP-43(A315T)-
expressing worms from day 1 of age, albeit this protective effect was not
consistently observed at all ages assessed; whereas significant
improvements of locomotion by MPS was consistently exhibited from
3 days of age (Fig. 5).
Notably, MPS and ethosuximide increased locomotion to a com-
parable extent despite a 160-fold difference in the external concentra-
tions applied. As ageing is linked with the development of many neu-
rodegenerative diseases, including ALS, the longevity effect of MPS on
TDP-43(A315T)-expressing worms was also investigated. Despite the
protective effects of 8mM ethosuximide on locomotion, the drug did
not significantly increase the shortened lifespan of these worms;
whereas 0.05mM MPS significantly increased mean lifespan by 25%
(Fig. 6).
ALS is characterised by the degeneration of upper and lower motor
neurons in the brain and spinal cord. To investigate if MPS has a direct
protective effect against neuronal degeneration, the integrity of the
GABAergic D-type inhibitory motor neurons was studied. These neu-
rons innervate the body wall muscles of the nematode, and are required
for ventral and dorsal muscle relaxation during locomotion. To visualise
GABAergic neurons specifically, the TDP-43(A315T)-expressing strain
was crossed with a transgenic strain containing GFP driven by the
promoter for the unc-25 gene, which encodes the GABA-synthesizing
enzyme glutamic acid decarboxylase (Jin et al., 1999). Due to the
Fig. 4. MPS concentration-response relationship
using a worm TDP-43 proteinopathy model. Body
bend frequencies of chronically-treated, age-syn-
chronised TDP-43(A315T)-expressing worms were
assessed to determine the concentration-response
relationship of the compound at various ages of
adulthood. (A) Body bends of control worms treated
with the 0.4% DMSO vehicle at all ages. Although
control values were not incorporated into con-
centration-response curves on the logarithmic scale
as a logarithmic value cannot be obtained for 0M of
the compound, body bend frequencies for each day
were compared against respective control values for
statistical analysis. Locomotion defects were not
ameliorated at any concentration on (B) days 1 and
(C) 3 (p > .05). (D - F) At older ages, locomotion
rate was significantly improved at concentrations of
−4.6M (0.025mM) and −4.3M (0.05mM)
(p < .05), although higher concentrations reduced
it instead. Data shown was pooled from three bio-
logical replicates, and comparisons were made with
the Kruskal-Wallis test with Dunn's multiple com-
parisons (n= 30 worms per day per concentration);
*, p < .05.
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Fig. 5. MPS ameliorates locomotion defects in the worm TDP-43 proteinopathy model. Age-synchronised worms were chronically treated with 8mM succinimide or
ethosuximide, 0.4% DMSO vehicle, or 0.05mMMPS in 0.4% DMSO from the L1 larval stage. Ethosuximide increased the frequency of body bends per minute at most
ages except days (B) 3 and (D) 7, whilst MPS consistently ameliorated locomotion defects from day 3 onwards (B-E; p < .05). Data shown was pooled from six
biological replicates. Comparisons were performed via the Kruskal-Wallis test with Dunn's multiple comparisons (n= 40–60 worms per day per treatment); *,
p < .05.
Fig. 6. MPS extends lifespan in the worm TDP-43
proteinopathy model. Lifespan analyses were per-
formed on age-synchronised worms chronically
treated from the L1 larval stage onwards. Worms
were scored as dead in the absence of pharyngeal
pumping or response to touch, with physically da-
maged and bagged worms censored from analysis.
(A) Ethosuximide had no effect on the lifespan
(p > .05), (B) whereas MPS improved the longevity
of the worms when compared to the DMSO control
(p < .05). Mean lifespans (number of adulthood
days) are as follows: succinimide, 12.45 ± 0.37
(n=141); ethosuximide, 13.08 ± 0.39 (n= 139);
DMSO, 11.51 ± 0.35 (n= 131); MPS,
14.37 ± 0.41 (n= 138). Data shown was pooled
from three biological replicates, with comparisons of
lifespans carried out with the log-rank test.
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transparency of C. elegans, the GFP-expressing GABAergic neurons can
be visualised in vivo at various adult ages to track age-dependent
neuronal changes. The cell bodies of the 19 GABAergic D-type in-
hibitory motor neurons lie along the ventral nerve cord and consist of
13 ventral (ventral D; VD) and 6 dorsal (dorsal D; DD) type neurons
which innervate the respective ventral and dorsal body wall muscles of
C. elegans.
The integrity of this neuronal subset was assessed by quantifying the
number of cell bodies and neuronal breaks in the ventral nerve cord, as
previously described (Liachko et al., 2010b); cell bodies were evident
from GFP punctae whereas discontinuities in the GFP fluorescence
along the nerve cord highlight neuronal breaks. Control worms ex-
hibited no significant neuronal damage even up to an adult age of day 7
(Fig. 7A,B). In contrast, TDP-43(A315T)-expressing worms suffered
significant cell body losses and neuronal breaks from the youngest as-
sessed age of day 1, verifying the neurodegenerative effect of the TDP-
43 mutation (Fig. S2; Fig. S3; Fig. S4; Fig. 7C,E). Both ethosuximide and
compound 9 conferred significant protection against cell body losses
and breaks within this motor neuronal subset (Figs. 7B,D, 8), demon-
strating that MPS ameliorates neurodegeneration with a similar efficacy
to ethosuximide but with over 100-fold increased potency.
3.4. Determining compound bioaccumulation using 1H NMR
One simple explanation for MPS's greatly increased potency relative
to ethosuximide could be that it bioaccumulates to higher levels within
the worm than those externally applied. This seems unlikely, as for
most compounds examined to date it has been shown that only a small
fraction of the externally applied concentration actually permeates the
worm's cuticle (Burns et al., 2010). Furthermore, the bioaccumulation
scores calculated using the C. elegans bioaccumulation prediction al-
gorithm (Burns et al., 2010) were very similar for ethosuximide and
MPS (Table S2). Nevertheless, to test this directly, we set out to measure
the bioaccumulation of applied compounds experimentally using 1H
NMR spectroscopy (Fig. S5). Initial analysis of succinimide, ethosux-
imide and MPS generated reference spectra for each compound; suc-
cinimide was included for comparison to exclude poor bioaccumulation
as a reason for its observed inactivity. Each compound yielded a unique
pattern of characteristic 1H peaks deriving from their chemical struc-
tures (Fig. S6). For the best detectable signal-to-noise ratio from worm-
derived metabolites, singlet peaks with the highest intensity for each
compound were selected for further analysis and calibration curves
were performed (Fig. S7) to enable subsequent quantification.
Fig. 7. Representative images of worms expressing
GFP in GABAergic neurons. Age-synchronised wild
type worms expressing GFP under the control of the
unc-25 promoter are shown at adult ages of (A) day 3
and (B) day 7 to compare the appearance of D-type
GABAergic motor neurons in the ventral nerve cord.
The 19 cell bodies of this neuronal subset manifest as
fluorescent punctae (indicated with arrows in A). (B)
Ageing did not cause observable physical neuronal
deterioration, which was evident from intact neu-
ronal tracts and discernible cell bodies at adult age
day 7. Images were taken at 200× magnification,
scale bars= 100 μm. (CeF) Age-synchronised TDP-
43(A315T)-expressing worms that also express GFP
under the control of the unc-25 promoter were
chronically treated with (A) 8 mM succinimide, (B)
8 mM ethosuximide, (C) 0.4% DMSO vehicle or (D)
0.05mM MPS in 0.4% DMSO from the L1 larval
stage. Breaks within the D-type GABAergic motor
neuron tracts in the ventral nerve cord are indicated
by red boxes, which are magnified in the inset red
boxes. Images were taken at 200× magnification,
scale bars= 100 μm. (For interpretation of the re-
ferences to colour in this figure legend, the reader is
referred to the web version of this article.)
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TDP-43(A315T)-expressing worms chronically treated with succi-
nimide, ethosuximide and MPS were lysed and extracted for 1H NMR
analysis. A small fraction of each worm extract was processed in par-
allel using SDS-PAGE, to enable quantification of worm numbers in
each sample by calculating total protein levels (Fig. S8). Following
extraction and NMR analysis, the strongest singlet peaks from succini-
mide and ethosuximide were readily observable in worm lysates
(Fig. 9A,B), whereas those from MPS were not detectable due to oc-
clusion from C. elegans endogenous metabolites (Fig. 9C). However, the
concentration of the externally administered MPS was 0.05mM, which
was 160-fold lower than the treatment concentration of 8mM for both
succinimide and ethosuximide. In an attempt to improve detectability
of the MPS singlet peak, worms were administered a 40-fold higher
concentration of the compound at 2mM, the highest tolerable con-
centration determined from concentration-response assessments
(Fig. 4). Nevertheless, this failed to distinguish the compound-9-derived
signal from internal metabolites (Fig. 9D). Due to potential occlusion of
this signal due to overlapping peaks from worm metabolites, other
MPS-derived peaks occupying separate spectral regions were examined
for both low and high concentrations of MPS. However, no distin-
guishable signals from the compound were visible at either con-
centration (Fig. 9E,F). The internal concentrations of succinimide and
ethosuximide in TDP-43-expressing worms were quantified based on
concentration and sample size standard curves (Fig. S7, Fig. S8). The
measured internal concentrations were 206.6 ± 48.89 μM for succini-
mide and 143.8 ± 39.08 μM for ethosuximide, representing
Fig. 8. MPS ameliorates GABAergic neurodegenera-
tion in the worm TDP-43 proteinopathy model. Age-
synchronised wild type and TDP-43(A315T) worms
expressing GFP under the control of the unc-25 pro-
moter were chronically treated with the indicated
compounds from the L1 larval stage onwards. (A-D)
Wild type worms consistently preserved more of the
19 D-type motor neuronal cell bodies than
TDP43(A315T) expressing worms at all assayed ages,
verifying neurodegenerative effect of the CK426
background (#, p < .05). Both ethosuximide (B-D)
and MPS (A, B and D) protected against cell body
losses in TDP-43 expressing worms when compared
against respective succinimide and DMSO controls
(p < .05). Data for wild type (n= 30 worms per age
point) and TDP-43 strains (n=33–47 worms per age
point) were pooled from two and three biological
replicates respectively.
(E-H) Wild type control worms had fewer neuronal
breaks than TDP-43 expressing worms at all ages, (#,
p < .05). Both ethosuximide and MPS reduced the
number of neuronal breaks in TDP-43 expressing
worms from day 3 onwards as compared to succini-
mide and DMSO controls (p < .05). Data for wild
type (n= 40 worms per age point) and TDP-43 ex-
pressing strains (n=43–56 worms per age point)
were pooled from three and four biological replicates
respectively. All statistical comparisons in A-H were
made via the Kruskal-Wallis test with Dunn's mul-
tiple comparisons; #, *, p < .05.
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approximately 2.5% of the externally applied concentration. Although
the lack of detectability of MPS prevents a precise estimate for its in-
ternal concentration, it seems reasonable to conclude that its greater
potency compared to ethosuximide is not due to it bioaccumulating to
high internal levels.
3.5. Mechanism of action of MPS
Having ruled out bioaccumulation, we reasoned that MPS's higher
potency could be explained either by a greater ability to activate the
same neuroprotective pathways as ethosuximide, or alternatively by
activation of a different mechanism. We and others have shown that
ethosuximide's neuroprotective and lifespan-extending effects in C.
elegans are dependent on the FOXO transcription factor, DAF-16
(Tauffenberger et al., 2013; Chen et al., 2015b). Therefore, we in-
troduced the null mutant daf-16(mu86) allele into our TDP-43(A315T)-
and GABAergic-GFP-expressing strain by genetic crossing, in order to
distinguish between these possibilities. The lifespan-extending effect of
MPS was abolished in these daf-16 mutant worms, as the mean lifespan
of MPS-treated worms was reduced by 3% in comparison to DMSO
controls (Fig. 10). Therefore, DAF-16 is essential for mediating the
longevity effects of MPS. As predicted based on the lack of lifespan
extension by ethosuximide described earlier (Fig. 6), the drug similarly
exhibited no effect on the lifespan of these daf-16 null worms (Fig. 10).
Loss of DAF-16 function also abolished the neuroprotective effects of
both compound 9 and ethosuximide as determined indirectly via lo-
comotion (Fig. 10) and directly via GABAergic neurodegeneration (Figs.
S9-S13). Therefore, we conclude that ethosuximide and MPS share a
common downstream neuroprotective mechanism of action that re-
quires DAF-16 transcription factor activity.
4. Discussion
Within the last 5 years, several different groups have independently
reported neuroprotective effects of the established anti-epileptic drug
ethosuximide in a variety of neurodegenerative disease models. These
range from C. elegans models of ALS (Tauffenberger et al., 2013),
frontotemporal dementia with parkinsonism-17 (Chen et al., 2015b)
and adult-onset neuronal ceroid lipofuscinosis (Chen et al., 2015b)); a
mammalian cell culture model of Huntington's disease (Chen et al.,
2015b); and a rat in vivo amyloid beta toxin-induced AD model (Tiwari
et al., 2015). Clearly, ethosuximide holds promise for repurposing as a
potential new treatment for neurodegenerative diseases, but the high
concentrations required for its effects and an unknown molecular me-
chanism of neuroprotective action represent significant challenges.
Here we have used a combination of chemoinformatics and phenotypic
screening using C. elegans to identify a novel neuroprotective activity of
the ethosuximide-related compound, α-methyl-α-phenylsuccinimide
(MPS). Importantly, MPS is as effective as ethosuximide in ameliorating
neurodegeneration despite being applied at a 160-fold lower external
Fig. 9. Determining compound bioaccumulation in
TDP-43(A315T) worms model worms using 1H NMR.
Overlay of spectra from lysates of chronically
treated, age-synchronised day 1 adult TDP-43 ex-
pressing worms are shown, emphasising regions with
compound-derived peaks of interest. (A) Succinimide
(2.82–2.74 ppm) and (B) ethosuximide-derived
peaks (1.30–1.28 ppm) were readily distinguishable
in samples treated with an 8mM external con-
centration of both compounds (red arrows). Peaks
common to compound-treated and non-treated ly-
sates arising from endogenous C. elegans metabolites
are also shown alongside compound-derived peaks
for comparison. Data shown are from nine 1H spectra
from three treatment conditions with three biolo-
gical replicates each. (For interpretation of the re-
ferences to colour in this figure legend, the reader is
referred to the web version of this article.)
(C,D) The singlet peak with the highest intensity
from MPS (red boxed region) was indistinguishable
from endogenous metabolites in samples treated
with either the optimal neuroprotective concentra-
tion of 0.05 mM (C) or the highest tolerable con-
centration of 2mM (D). Due to the undetectability of
the singlet peak, the presence of other compound-
derived multiplet peaks in the aromatic (E) or –CH2
(F) region were analysed from spectra derived from
treatment with both low and high concentrations. To
facilitate peak identification from these multiplets,
the reference spectrum of the pure compound was
overlaid with those from treated worm lysates; re-
ference peaks as shown in yellow and indicated with
black arrows. These peaks were also not detectable
from samples. Data shown is from nine 1H spectra
from three treatment conditions with three biolo-
gical replicates each.
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concentration. MPS was undetectable by NMR in worm extracts, likely
due to occlusion of the expected peak regions by endogenous metabo-
lites. Alternatively, it could be that MPS was further metabolized into
another compound that may itself possess bioactivity. The only re-
ported metabolites of MPS are its para-hydroxylation product, α-(p-
hydroxyphenyl)-α-methylsuccinimide, and a glucuronidate-conjugated
form of this molecule (Dudley et al., 1974). However, we were unable
to detect the predicted NMR signals corresponding specifically to these
reported metabolites, or indeed for any other potential MPS-derived
signals in NMR spectra using metabolomic analysis. Hence, MPS and
any putative metabolite(s) are evidently undetectable by NMR, pre-
sumably due to rapid clearance and/or occlusion of peaks by strong
signals from endogenous worm metabolites. This therefore precludes a
precise value for MPS's effective therapeutic concentration within the
worm. Nevertheless, as the calculated C. elegans bioaccumulation scores
for ethosuximide and MPS are similar; and as we and others (Evason
et al., 2005) have shown that only 1–5% of external applied ethosux-
imide bioaccumulates inside worms; it seems reasonable to assume that
the optimal externally applied concentration of 0.05mM MPS corre-
sponds to a sub-micromolar internal concentration inside the worm.
Fig. 10. DAF-16 is essential for lifespan extension
and neuroprotection by MPS.
(A-B) Lifespan analyses were performed in chroni-
cally-treated daf-16 null TDP-43(A315T) worms.
Animals were scored as dead in the absence of
pharyngeal pumping or response to touch, with
physically damaged and bagged worms censored
from analysis. Both ethosuximide (A) and MPS (B)
failed to increase longevity in the absence of func-
tional DAF-16 (p > .05). Mean lifespans (number of
adulthood days) are as follows: succinimide,
11.70 ± 0.34 (n=86); ethosuximide, 11.30 ±
0.33 (n= 87); DMSO, 12.03 ± 0.40 (n=77); MPS,
11.65 ± 0.32 (n=86). Data shown was pooled
from two biological replicates, with comparisons of
lifespans carried out with the log-rank test.
(C-G) The ability of ethosuximide and MPS to miti-
gate the locomotion defects of TDP-43(A315T)
worms was abolished by mutation of daf-16. Data
was pooled from three biological replicates, with
comparisons performed via the Kruskal-Wallis test
with Dunn's multiple comparisons against the ap-
propriate succinimide or DMSO controls (n=26–30
worms per treatment per age point).
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This should facilitate future identification of the direct molecular tar-
gets of MPS using affinity chromatography/proteomic approaches,
which has recently been optimised to identify the protein targets of
various small molecules with low micromolar binding affinities (Ong
et al., 2009). Furthermore, MPS provides more flexibility than etho-
suximide for making chemical modifications to enable linkage to affi-
nity matrices, by virtue of its phenyl moiety. Given that we have shown
here that ethosuximide and MPS share a common downstream me-
chanism of action requiring the DAF-16 transcription factor, it seems
likely that such studies would also shed light on ethosuximide's cur-
rently unclear molecular mechanisms of action in both epilepsy and
neuroprotection. Interestingly, several other neuroprotective com-
pounds are also dependent on DAF-16, including steroids, polyphenols,
lithium and metformin, suggesting that a comparative network analysis
of these drugs and their targets could also shed light on the molecular
mechanism of action of MPS and ethosuximide (Chen et al., 2015a;
Farina et al., 2017). In addition, the ease of chemical modification of
MPS will also facilitate future medicinal chemistry studies to find even
more potent 2nd-generation succinimide-based neuroprotective agents.
MPS's high MPO scores indicating likely good CNS penetration after
oral delivery suggest that the MPS scaffold is a suitable starting point
for such medicinal chemistry optimisation.
MPS is the active metabolite of the existing clinically approved AED,
methsuximide. Indeed, methsuximide is a pro-drug that is demethylated
in vivo to yield N-desmethylmethsuximide, which is identical to MPS
and is responsible for its antiepileptic effects in patients (Strong et al.,
1974). Methsuximide may therefore have translational potential for
repurposing to treat TDP-43 proteinopathies. Interestingly, methsux-
imide is effective against a variety of different forms of epilepsy, in-
cluding complex partial seizures (Wilder and Buchanan, 1981; Browne
et al., 1983), intractable childhood seizures (Tennison et al., 1991;
Sigler et al., 2001) and juvenile myoclonic epilepsy (Hurst, 1996);
whereas ethosuximide is only effective against absence seizures (Goren
and Onat, 2007). These differences are also seen in rodents, where
ethosuximide is effective solely in the PTZ seizure model whereas
methsuximide also prevents maximal electroshock-induced seizures
(Chen et al., 1963). This may suggest that the two drugs have different
therapeutic mechanisms of action in epilepsy; or alternatively that
ethosuximide can prevent convulsive seizures, but only at high doses
that induce toxicity in patients. Our findings here that ethosuximide
and MPS share a common downstream DAF-16-dependent mechanism
of neuroprotective action support the latter hypothesis; as does the
observation that ethosuximide is capable of preventing maximal elec-
troshock-induced seizures in mice, albeit at an ED50 that is 20-fold
higher than methsuximide and is accompanied by anaesthetic effects
(Chen et al., 1963). High doses of the methsuximide pro-drug have been
associated with toxicity due to serum MPS levels of over 0.2 mM (Sigler
et al., 2001), which could hinder its therapeutic use in neurodegen-
erative disease. However, given that we have shown here that MPS
ameliorates neurodegeneration in C. elegans at a much lower con-
centration than this, it may be that methsuximide would have neuro-
protective activity at lower doses than used for treatment of epilepsy,
which may avoid such adverse effects. Once converted from the pro-
drug methsuximide, MPS has a long half-life of 38–70 h in humans
(Strong et al., 1974; Porter et al., 1979), so relatively infrequent low
oral doses of methsuximide could potentially provide long-lasting
neuroprotection.
5. Conclusion
MPS is a novel neuroprotective molecule that is more than two
orders of magnitude more potent than the related molecule, ethosux-
imide. Its increased potency will aid future efforts to identify the cur-
rently unknown direct molecular targets of both MPS and ethosux-
imide, given that they share a common downstream neuroprotective
mechanism of action. As MPS is the active metabolite of the
antiepileptic pro-drug, methsuximide, treatment with low doses of
methsuximide could potentially be considered as a treatment for TDP-
43 proteinopathies such as amyotrophic lateral sclerosis and FTLD-TDP,
and possibly other human neurodegenerative diseases.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nbd.2018.06.013.
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